Focus: Adverum Biotechnologies is a gene therapy company specializing in adeno-associated virus (AAV) delivery platforms, primarily focused on ophthalmologic and rare genetic diseases. The company operates as a clinical-stage biotech with a concentrated pipeline in retinal and systemic indications.
Profile data last refreshed 3h ago · AI intelligence enriched 3w ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Adverum is a focused gene therapy play with meaningful clinical catalysts, but limited hiring and opaque finances make it suitable only for risk-tolerant candidates seeking deep technical involvement in early-stage AAV programs.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Adverum Biotechnologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Adverum Biotechnologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo